Trial reportThe American journal on addictions2016
Vilazodone for cannabis dependence: A randomized, controlled pilot trial.
Trial report in The American journal on addictions, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Pharmacotherapies for cannabis use disorder.The Cochrane database of systematic reviews · 2025Pooled it
- Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis.The International journal on drug policy · 2021Pooled it
- Sex- and Gender-Based Analysis in Cannabis Treatment Outcomes: A Systematic Review.International journal of environmental research and public health · 2020Pooled it
- Pharmacotherapies for cannabis dependence.The Cochrane database of systematic reviews · 2019Pooled it
- Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder.Drug and alcohol dependence · 2019Pooled it
- A preliminary randomized controlled trial of repetitive transcranial magnetic stimulation applied to the left dorsolateral prefrontal cortex in treatment seeking participants with cannabis use disorder.Drug and alcohol dependence · 2024Trial
- Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.Psychopharmacology · 2020Trial
- Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials.Drug and alcohol dependence · 2018Trial
- Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study.The American journal on addictions · 2017Trial
- Cannabis craving and cross-substance substitution during cannabis treatment: Initial insights across seven cannabis use disorder clinical trials.Addictive behaviors · 2026Article
- Not just neurons: glial mechanisms driving sex-specific vulnerability to withdrawal and relapse in substance use disorder.Frontiers in neuroendocrinology · 2026Review
- Drugs repurposed against morphine and heroin dependence: molecular docking, DFT, MM-GBSA-based MD simulation studies.In silico pharmacology · 2025Article
- Association of Cannabis Use Reduction With Improved Functional Outcomes: An Exploratory Aggregated Analysis From Seven Cannabis Use Disorder Treatment Trials to Extract Data-Driven Cannabis Reduction Metrics.The American journal of psychiatry · 2024Article
- Review
- Biological sex and hormonal contraceptive associations with drug cue reactivity in cannabis use disorder.Journal of psychiatric research · 2024Article
- Treatments for Cannabis Use Disorder across the Lifespan: A Systematic Review.Brain sciences · 2024Review
- Consideration of sex and gender differences in addiction medication response.Biology of sex differences · 2022Review
- Cannabis Affects Cerebellar Volume and Sleep Differently in Men and Women.Frontiers in psychiatry · 2021Article
- Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers.Addiction biology · 2019Article
- Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesThe purpose of this study was to evaluate the efficacy of vilazodone, a selective serotonin receptor inhibitor and partial 5-HT1A agonist, for treatment of cannabis dependence.
methodsSeventy-six cannabis-dependent adults were randomized to receive either up to 40 mg/day of vilazodone (n = 41) or placebo (n = 35) for 8 weeks combined with a brief motivational enhancement therapy intervention and contingency management to encourage study retention. Cannabis use outcomes were assessed via weekly urine cannabinoid tests; secondary outcomes included cannabis use self-report and cannabis craving.
resultsParticipants in both groups reported reduced self-reported cannabis use over the course of the study; however, vilazodone provided no advantage over placebo in reducing cannabis use. Men had significantly lower creatinine-adjusted cannabinoid levels and a trend for increased negative urine cannabinoid tests than women. DISCUSSION AND
conclusionsVilazodone was not more efficacious than placebo in reducing cannabis use. Important gender differences were noted, with women having worse cannabis use outcomes than men. SCIENTIFIC SIGNIFICANCE: Further medication development efforts for cannabis use disorders are needed, and gender should be considered as an important variable in future trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.